NCT01253694
Withdrawn
Phase 2
Ranibizumab in Residual Diabetic Macular Edema Following Previous Intravitreal Bevacizumab Therapy
ConditionsDiabetic Macular Edema
Interventionsinjection of 0.5 mg of Intravitreal Ranibizumab
Overview
- Phase
- Phase 2
- Intervention
- injection of 0.5 mg of Intravitreal Ranibizumab
- Conditions
- Diabetic Macular Edema
- Sponsor
- New England Retina Associates
- Locations
- 1
- Primary Endpoint
- Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis < 300 microns.
- Status
- Withdrawn
- Last Updated
- 13 years ago
Overview
Brief Summary
Treatment with Ranibizumab of the residual diabetic edema in patients with failed response to Bevacizumab.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects will be eligible if the following criteria are met:
- •Age \> 18 years
- •Diagnosis of diabetes mellitus (type 1 or 2)
- •Residual edema as determined by mean foveal thickness on Spectralis OCT (optical coherence tomography) \> 300 microns and leakage seen on FA at baseline
- •Clinical evidence of retinal thickening due to macular edema involving the center of the macula, associated with diabetic retinopathy.
- •Previous history of at least 3-5 or more consecutive 1.25 mg of intravitreal bevacizumab injections for the treatment of diabetic macular edema (consecutive injections administered no more than 6 weeks apart).
- •BCVA of 20/32-20/400 using Early Treatment Diabetic Retinopathy Study (ETDRS)
- •Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Criteria
- •Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.
- •Participation in another ocular investigation or trial simultaneously.
- •Systemic use of anti-VEGF within 3 months prior to day
- •Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110)
- •Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse).
- •Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be contributing to the macular edema.
- •An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis, ischemic maculopathy or geographic atrophy).
- •Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. Age-related Macular Degeneration, uveitis, Irvine-Gass).
- •Evidence of active neovascularization of the iris or retina.
- •Evidence of central atrophy or fibrosis in the study eye.
Arms & Interventions
Patients with 3-5 consecutive Avastin injections
These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
Intervention: injection of 0.5 mg of Intravitreal Ranibizumab
Patients with 6 or more consecutive injections of Bevacizumab
Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
Intervention: injection of 0.5 mg of Intravitreal Ranibizumab
Outcomes
Primary Outcomes
Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis < 300 microns.
Time Frame: 6 months
Secondary Outcomes
- Evaluate the main change in BCVA (best corrected visual acuity) score over time(6-12 months)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF TherapyDiabetic Macular EdemaNCT01472510Vitreo-Retinal Associates, PC20
Completed
Not Applicable
Evaluation of Ranibizumab for diabetes macular edemadiabetes macular edemaJPRN-UMIN000001984Yamagata University faculty of Medecine,department of ophthalmology10
Completed
Phase 2
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) StudyDiabetic Macular EdemaNCT00407381Johns Hopkins University126
Completed
Phase 4
Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment EvaluationDiabetic RetinopathyNCT01223612Moorfields Eye Hospital NHS Foundation Trust37
Completed
Not Applicable
Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)Diabetic Macular EdemaNCT05815212Novartis Pharmaceuticals87